1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2,...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 207/08 (2006.01) A61K 31/40 (2006.01) A61P 11/06 (2006.01) C07D 211/34 (2006.01)

Patent

CA 2525801

This invention is directed to compounds of formula (I): wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.

La présente invention concerne des composés représentés par la formule générale (I) dans laquelle R?1¿-R?5¿ et a-e sont des éléments définis dans la description ; ou des sels ou des solvates ou encore des stéréo-isomères de qualité pharmaceutique de ces composés. L'invention concerne également des compositions pharmaceutiques contenant ces composés ; des procédés et des produits intermédiaires destinés à la préparation de ces composés ; ainsi que des méthodes destinées au traitement d'états pathologiques induits par les récepteurs muscariniques, utilisant ces composés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1738771

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.